RxDoctor Payments Data

Stephanie Lirio, MD

Child & Adolescent Psychiatry · Sarasota, FLNPI 1558450817

Payments from drug & device makers

$1,011in general payments, 2019–2025

Across 46 payments — averaging $21.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$447
  • Neuronetics, Inc.$195
  • AbbVie$120
  • Ironshore Pharmaceuticals Inc.$63
  • Takeda Pharmaceuticals U.S.A., Inc.$54
  • GSK$47
  • plus $85 from 5 others

What the payments were for

  • Food & beverage$98197%
  • Education$303%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson23$447
Neuronetics, Inc.1$195
AbbVie(2 entities)6$120
Ironshore Pharmaceuticals Inc.4$63
Takeda Pharmaceuticals U.S.A., Inc.3$54
GSK3$47
Axsome Therapeutics, Inc.1$29
Alfasigma USA, Inc.1$21
Neos Therapeutics, LP1$12
Corium, LLC2$12
TMS Neurohealth Centers Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,011 in reported general payments places this provider in the 60th percentile of 206 child & adolescent psychiatry providers in Florida.

See all child & adolescent psychiatry providers in Florida

Medicare billing

Part B allowed, 2024
$234,434
Medicare patients
60
Services billed
2,036

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SpravatoEsketamine Hcl337$436,754
TrintellixVortioxetine Hydrobromide19$10,243
Aripiprazole22$4,632
Bupropion XlBupropion Hcl89$3,135
Duloxetine Hcl34$2,045
Quetiapine Fumarate58$841
Alprazolam79$794
Clonazepam40$686
Mirtazapine22$626
Lamotrigine20$502
Fluoxetine Hcl31$457
Venlafaxine Hcl ErVenlafaxine Hcl13$426
Gabapentin19$399
Trazodone Hcl30$331
Sertraline Hcl18$330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonSpravato$447$436,754337 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$54$10,24319 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 206 child & adolescent psychiatry providers in Florida.

Other child & adolescent psychiatry in Sarasota

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →